StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Posted by ABMN Staff on May 8th, 2024

Research analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Stock Down 1.9 %

Shares of CANF stock opened at $2.07 on Wednesday. The company has a market capitalization of $7.33 million, a price-to-earnings ratio of -1.16 and a beta of 1.58. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $3.33. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $2.10.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities analysts expect that Can-Fite BioPharma will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC bought a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned 0.57% of Can-Fite BioPharma at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.